Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa

This publication has 28 references indexed in Scilit:

• Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study
  British Journal of Haematology, 2003
• Randomized, dose‐finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies
  British Journal of Haematology, 2002
• Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy
  JNCI Journal of the National Cancer Institute, 2002
• Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
  British Journal of Cancer, 2002
• Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies
  Journal of Clinical Oncology, 2002
• Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
  Journal of Clinical Oncology, 2001
• Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing
  Journal of Clinical Oncology, 2001
• Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
  JNCI Journal of the National Cancer Institute, 1999
• Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
  Journal of Clinical Oncology, 1998
• Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
  Journal of Clinical Oncology, 1997